Adaptin Bio (APTN) Gains from Investment Securities (2024 - 2026)

Adaptin Bio (APTN) has 3 years of Gains from Investment Securities data on file, last reported at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities rose 22606.89% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (up 6060.32% YoY), and the FY2025 full-year result was $6312.0, down 63.06% from the prior year.
• Gains from Investment Securities advanced to $1.4 million in Q1 2026, from $6312.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $1.4 million in Q1 2026 to a low of $133.0 in Q1 2024.
• A 3-year average of $242776.3 and a median of $6280.5 in 2024 frame the typical range for Gains from Investment Securities.
• Across the five-year window, Gains from Investment Securities surged 4645.86% in 2025 and soared 22606.89% in 2026, its largest moves.
• Tracing APTN's Gains from Investment Securities over 3 years: stood at $8332.0 in 2024, then declined by 24.24% to $6312.0 in 2025, then soared by 22606.89% to $1.4 million in 2026.
• Business Quant data shows APTN's Gains from Investment Securities at $1.4 million in Q1 2026, $6312.0 in Q1 2025, and $8332.0 in Q4 2024.